Results 11 to 20 of about 15,200 (191)

Why We Do Not Recommend That People With High-Risk Smoldering Myeloma Receive Treatment. [PDF]

Am J Hematol
American Journal of Hematology, Volume 101, Issue 3, Page 409-412, March 2026.
Mohyuddin GR, Lemieux M, Chakraborty R, Gertz M.   +3 more
europepmc   +2 more sources

Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth

Experimental Hematology & Oncology, 2018
Background The monoclonal antibody daratumumab, approved for treating myeloma, targets CD38, a protein on myeloma and also on CD34+ hematopoietic progenitor cells.
Xun Ma, Sandy W. Wong, Ping Zhou, Chakra P. Chaulagain, Parul Doshi, Andreas K. Klein, Kellie Sprague, Adin Kugelmass, Denis Toskic, Melissa Warner, Kenneth B. Miller, Lisa Lee, Cindy Varga, Raymond L. Comenzo   +13 more
doaj   +1 more source

Refractory Periorbital Necrobiotic Xanthogranuloma Treated With Plasma Cell-Directed Therapy. [PDF]

EJHaem
eJHaem, Volume 7, Issue 1, February 2026.
Trando A, Jeong AR, Goodman AM.
europepmc   +2 more sources

Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival

Haematologica, 2023
Treatment of patients with Mayo stage IIIb light chain (AL) amyloidosis is still challenging, and the prognosis remains very poor. Mayo stage IIIb patients were excluded from the pivotal trial leading to the approval of daratumumab in combination with ...
Sara Oubari, Ute Hegenbart, Renate Schoder, Maximilian Steinhardt, Maria Papathanasiou, Tienush Rassaf, Andreas Thimm, Tim Hagenacker, Eyad Naser, Ulrich Duhrsen, Hans C. Reinhardt, Martin Kortum, Hermine Agis, Stefan Schonland, Alexander Carpinteiro   +14 more
doaj   +1 more source

Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens

Haematologica, 2020
CD38 is expressed in several types of non-Hodgkin lymphoma (NHL) and constitutes a promising target for antibody-based therapy. Daratumumab (Darzalex) is a first-in-class anti-CD38 antibody approved for the treatment of relapsed/refractory (R/R) multiple
Anna Vidal-Crespo, Alba Matas-Céspedes, Vanina Rodriguez, Cédric Rossi, Juan G. Valero, Neus Serrat, Alejandra Sanjuan-Pla, Pablo Menéndez, Gaël Roué, Armando López-Guillermo, Eva Giné, Elías Campo, Dolors Colomer, Christine Bezombes, Jeroen Lammerts van Bueren, Christopher Chiu, Parul Doshi, Patricia Pérez-Galán   +17 more
doaj   +1 more source

Relapsed/refractory multiple myeloma-transformed plasma-cell leukemia successfully treated with daratumumab followed by autologous stem cell transplantation

Therapeutic Advances in Hematology, 2021
Daratumumab is a humanized anti-CD38 IgG1 monoclonal antibody which could be used for multiple myeloma (MM). MM with plasma-cell leukemia (PCL) transformation is highly aggressive and is resistant to conventional therapy.
Chen-lu Yang, Neng-gang Jiang, Li Zhang, Kai Shen, Yu Wu   +4 more
doaj   +1 more source

Efficacy and safety of daratumumab in the treatment of multiple myeloma: a systematic review and meta-analysis

Journal of International Medical Research, 2021
Objective To systematically evaluate the efficacy and safety of combination regimens containing daratumumab in patients with multiple myeloma (MM). Methods A systematic search of publications listed on electronic databases (PubMed®, The Cochrane Library,
Yin Wang, Yanqing Li, Ye Chai
doaj   +1 more source

Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma [PDF]

, 2017
New therapeutic strategies are urgently needed to improve clinical outcomes in patients with multiple myeloma (MM). Daratumumab is a first-in-class, CD38 human immunoglobulin G1κ monoclonal antibody approved for treatment of relapsed or refractory MM ...
Ahmadi, Tahamtan, Clemens, Pamela L, Jansson, Richard, Khan, Imran, Liu, Kevin, Lokhorst, Henk M, Lonial, Sagar, Perez Ruixo, Juan Jose, Plesner, Torben, Puchalski, Thomas, Voorhees, Peter M, Xu, Xu Steven, Yan, Xiaoyu, Zhou, Honghui   +13 more
core   +1 more source

New Methods in Treatment of Renal failure in Patients with Multiple Myeloma: A Review with Immunological Approach. [PDF]

, 2017
Multiple myeloma (MM), as one of a variety of autoimmune diseases, affects the immune system and, on the other hand, is considered to be a hematologic impairment.
Iranparast, Sara., Saeedi-Boroujeni, Ali., Shirani, Majid.   +2 more
core   +1 more source

Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma

Blood Advances, 2017
: Daratumumab, a human CD38 imunoglobulin G 1κ monoclonal antibody, has demonstrated clinical activity and a manageable safety profile in monotherapy and combination therapy clinical trials in relapsed and/or refractory multiple myeloma.
Tineke Casneuf, Xu Steven Xu, Homer C. Adams, III, Amy E. Axel, Christopher Chiu, Imran Khan, Tahamtan Ahmadi, Xiaoyu Yan, Sagar Lonial, Torben Plesner, Henk M. Lokhorst, Niels W.C.J. van de Donk, Pamela L. Clemens, A. Kate Sasser   +13 more
doaj   +1 more source